Press Releases April 6, 2026 08:00 PM

Amneal to Report First Quarter 2026 Results on May 1, 2026

Amneal Pharmaceuticals Announces Q1 2026 Earnings Release Date and Webcast

By Derek Hwang AMRX

Amneal Pharmaceuticals, a diversified global biopharmaceutical company, will report its first quarter 2026 financial results on May 1, 2026, prior to market open, with a live webcast and conference call available for investors.

Amneal to Report First Quarter 2026 Results on May 1, 2026
AMRX

Key Points

  • Amneal will release Q1 2026 financial results on May 1, 2026, followed by an investor webcast and conference call.
  • The company is a diversified biopharmaceutical leader with a portfolio of approximately 300 complex, specialty and biosimilar medicines.
  • Amneal operates through segments including Affordable Medicines, Specialty branded treatments in neurology and endocrinology, and AvKARE distribution to federal, retail, and institutional customers.

BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its first quarter 2026 financial results on Friday, May 1, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call is 458312872. A replay of the conference call will be posted shortly after the call.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail, injectable, and biosimilar products. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit www.amneal.com and follow us on LinkedIn.

Investor Contact
Anthony DiMeo
VP, Investor Relations
[email protected]


Risks

  • Financial results could be negatively impacted by market or regulatory factors affecting pharmaceutical sales and product approval.
  • The company's reliance on the U.S. market and healthcare regulations poses exposure to policy changes and reimbursement challenges.
  • Competition in the generic, specialty, and biosimilar medicine sectors could impact market share and profitability.

More from Press Releases

Google Research and Synaptics Partner to Showcase Immersive Edge AI experiences powered by the Coralboard™ at Google I/O 2026 May 19, 2026 GE Aerospace Awarded U.S. Air Force Contract to Advance GE426 Engine for Autonomous Collaborative Platform May 19, 2026 Oliver James to Lead MainStreet Bank’s Commercial and Government Contract Lending Team May 19, 2026 Vishay Intertechnology to Showcase Power Electronics Solutions Enabling Electrification, Efficiency, and System Integration at PCIM Europe 2026 May 19, 2026 Amanat Acquisition Corp Announces Pricing of $75 Million Initial Public Offering May 19, 2026